Retrospective Analysis of the Four Seasons Antiviral Admixture in the Treatment of SARS-CoV-2 Infection in Children
DOI:
https://doi.org/10.53469/jcmp.2024.06(07).26Keywords:
The four seasons antiviral admixture, Children, SARS-CoV-2 infection, Virus toxicity bundle syndromeAbstract
Objective: To conduct a retrospective analysis, evaluate the clinical efficacy of the four seasons antiviral admixture, and provide clinical basis for the treatment of novel coronavirus infection in children. Methods: Using a clinical retrospective study method, A total of 102 children from the Second Affiliated Hospital of Shaanxi University of Chinese Medicine who met the diagnostic criteria of pediatric SARS-CoV-2 were collected, Randomized into control group (conventional western medicine treatment), 51 cases in the observation group (using four seasons antiviral admixture in the control group), Compare the changes of fever duration, the duration of cough, hospital stay, and before and after treatment (white ocyte count, percentage, percentage of lymphocytes, monocytes, C reactive protein, interleukin-6, sedimentation rate, creatine kinase isoenzyme, myoglobin, hypersensitive troponin I). Results: The cure rate was 76.47%, significantly higher than that of the control group (P <0.05); the difference between fever and duration of cough and hospitalization days in the observation and control groups (P <0.05); WBC count, central cell percentage, monocyte percentage, C reactive protein, interleukin-6, blood loss, increase of lymphocyte percentage and the difference (P <0.05); and no adverse events occurred after treatment. Conclusion: Four seasons antiviral admixture can significantly shorten the duration of fever, cough and hospitalization in children with novel coronavirus infection, effectively improve the infection index and myocardial injury index in children, and be safe and reliable.
References
National Health Comission of the People’s Republic China. Diagnosis and treatment plan for COVID-19 (trial version 10) [J]. Chinese Journal of Clinical Infectious Diseases, 2012, 16(1):1-9.
Jian Rongmeng. Diagnosis, treatment and prevention of severe acute respiratory syndrome coronavirus 2 infection in children: experts′ consensus statement (Fifth Edition) updated for the Omicron variant[J]. Chinese Journal of Applied Clinical Pediatrics, 2023, 1(38):20-30.
Hansen CH, Michlmayr D, Gubbels SM, et al. Assessment of protection against reinfection with SARS-CoV-2 among 4 million PCR-tested individuals in Denmark in 2020: a population-level observational study[J]. Lancet, 2021, 397(10280):1204-1212.
Mu Xuechun, Wang Linhan. Advances in the study of novel coronavirus reinfection[J]. National Medical Journal of China, 2022, 102(40):3229-3232.
Cui X, Zhao Z, Zhang T, et al. A systematic review and meta-analysis of children with coronavirus disease 2019 (COVID-19) [J]. J Med Virol, 2021, 93(2): 1057-1069.
Ren W, Liang P, Ma Y, et al. Research progress of traditional Chinese medicine against COVID-19[J]. Biomed Pharmacother, 2021, 137: 111310.
Cui Heqing. Characteristics of Epidemic Febrile Disease Differentiation and Treatment in YE Tianshi and Its Enlightenment to Prevention and Treatment of Novel Coronavirus Infection in Children[J]. Chinese Archives of Traditional Chinese Medicine, 2023. 41(02): 15-18.
Ma XF, Liu SS, Chen LZ, et al. The clinical characteristics of pediatric inpatients with SARS-CoV-2 infection: A meta-analysis and systematic review[J]. J Med Virol, 2021. 93(1): 234-240.
Zhang Yifei. Clinical features of severe acute respiratory syndrome coronavirus 2 Omicron variant infection in children: an analysis of 201 cases[J]. Chinese Journal of Contemporary Pediatrics, 2023, 25(1): 5-10.
Shan Sisi, Yang Ziqin, Zhang linqi. Research Progress on Antibody Therapies Against SARS-CoV-2 Received US FDA Emergency Use Authorization[J].Chinese Journal of Medical Guide, 2022, 24(1): 9-15.
Shorobi FM, Nisa FY, Saha S, et al. Quercetin: A Functional Food-Flavonoid Incredibly Attenuates Emerging and Re-Emerging Viral Infections through Immunomodulatory Actions[J]. Molecules, 2023, 17, 28(3): 938.
Wilson JC, von Itzstein M. Recent strategies in the search for new anti-influenza therapies[J]. Curr Drug Targets, 2003, 4(5): 389-408.
Feng H, Chen G, Zhang Y, et al. Potential Multifunctional Bioactive Compou nds from Dysosma versipellis Explored by Bioaffinity Ultrafiltration - HPLC/MS with Topo I, Topo II, COX-2 and ACE2[J]. J Inflamm Res, 2022, 15, 15:4677-4692.
Yu R, Chen L, Lan R, et al. Computational screening of antagonists against the SARS-CoV-2 (COVID-19) coronavirus by molecular docking[J]. Int J Antimicrob A gents, 2020, 56(2):106012.
Zhu J, Yan H, Shi M, et al. Luteolin inhibits spike protein of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) binding to angiotensin - converting enzyme 2. Phytother Res, 2023, 37(8):3508-3521.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Xixia Wang, Yile Kou, Qian Bai, Weihua Zhang, Shasha Liu, Hui Ding
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
